Introduction
============

Notoginseng, the root of *Panax notoginseng* (Burk.) F. H. Chen (*P. notoginseng*), also called Sanqi or Sanchi, is a precious traditional Chinese medical drug which has a history of medical use for over 400 years. The main active components of notoginseng include saponins, dencichine, flavonoids, polysaccharides and fatty acids, etc. ([@B89], [@B94]). Although some non-saponin constitutents exhibit hemostasis, neuroprotective and immunity activities ([@B18]; [@B19]), a majority of the pharmacological functions of notoginseng are basically attributed to its saponin components ([@B75]). Contemporary research have discovered that *Panax notoginseng* saponins (PNS) can be effective in the treatment of cardiovascular diseases ([@B106]), such as atherosclerosis ([@B45]), hypertension ([@B59]), myocardial ischemia ([@B17]), and aortic intimal hyperplasia ([@B98]), etc. Moreover, PNS also possesses the biological activities of anti-cancer ([@B105]), anti-hyperlipoidemia ([@B101]), anti-hyperglycemia ([@B103]), anti-inflammatory response ([@B72]), anti-depression ([@B102]), neuroprotective effect ([@B51]), antioxidative effect ([@B111]), and bone formation stimulation activity ([@B4]), etc.

Unlike its close relatives, i.e., *Panax ginseng* and *Panax quinque foilium, P. notoginseng* possesses dammarane-type tetracyclic triterpenoid saponins exclusively ([@B89]), and the total amount of dammarane-type saponins in *P. notoginseng* is evidently greater than that in the other two species ([@B86]). Dammarane-type saponins can essentially be divided into two groups: protopanaxadiol (PPD) and protopanaxatriol (PPT) type. Both of PPD and PPT aglycons bear chiral carbons in their structure skeletons, which lead to the stereoisomerism of PPD and PPT saponins (**Figures [1A](#F1){ref-type="fig"}--[D](#F1){ref-type="fig"}**). Interestingly, although stereoisomeric compounds are widely distributed in herbal medical drugs, the chemical and pharmacological difference in stereoisomers in phytochemistry has not been extensively studied until recently, and the research targets include triterpenoid saponins ([@B57]), flavanones ([@B71]), Schisandrin B ([@B50]), alkaloids ([@B32]), fatty acids ([@B56]), and pyranocoumarins ([@B77]).

![Structure skeletons of saponins existed in raw and processed *P. notoginseng*. The different substituents represented by R1, R2, and R3 in structures of **(A--N)** have been elaborated in **Table [1](#T1A){ref-type="table"}**.](fphar-09-00188-g001){#F1}

The investigation on C-20 stereoisomerism of dammarane-type saponins has aroused the interest of researchers in recent years. Generally speaking, stereoisomerism in phytochemistry refers to optical and geometric isomerism, respectively. Not surprisingly, raw notoginseng is discovered to contain 20(S)-optical isomer of saponins basically, such as 20(S)-notoginsengoside R~2~, 20(S)-ginsenoside Rg~2~ and 20(S)-ginsenoside Rh~1~. However, it has been demonstrated that the processing procedures of *P. notoginseng*, e.g., steaming, heating, frying, etc., may lead to the cleavage of glycosyl linkage bonds and the dehydration at C-20. During the processes, some originally existed saponins in raw notoginseng would gradually be deglycosylated at C-20 to optical saponin epimers, such as 20(S)-/20(R)-ginsenoside Rg~3~ and 20(S)-/20(R)-ginsenoside Rh~2~, as well as be dehydrated at C-20 to geometric isomers, i.e., *cis-trans* isomers, such as ginsenoside RK~3~ and Rh~4~, RK~1~ and Rg~5~, RK~2~ and Rh~3~, etc. (**Figures [1E](#F1){ref-type="fig"}--[H](#F1){ref-type="fig"}**) ([@B90]). Based on previously published studies, some secondary saponins are of high biological activities compared with the original ones in raw *P. notoginseng*. So far, literatures have indicated that saponin stereoisomers may exhibit significant difference in the following aspects: (1) physical and chemical properties; (2) methods of isolation, analysis and preparation; (3) biological, pharmacological, pharmacodynamic, and clinical evaluations; (4) key parameters of pharmacokinetics. However, the biotechnological difference of the stereoisomers of saponins in notoginseng has not been extensively reviewed so far. This article compiles a review of chemical compositions of raw and processed notoginseng with a particular emphasis on the stereoisomeric saponins. Besides, the determination, preparation methods, and the pharmacological and pharmacokinetic researches of those saponin stereoisomers are also elaborated.

Chemistry
=========

Dammarane-Type Saponins in Raw *P. notoginseng*
-----------------------------------------------

So far extensive researches have been performed on the identification and analysis of saponins in raw *P. notoginseng*. The nomenclatures of the saponins isolated from *P. notoginseng* are generally ginsenoside and notoginsenoside. One distinguishing feature of notoginseng is that all of the saponins can be classified into PPD, PPT or their derivative types. However, the saponins profiles in different medicinal parts, e.g., root, rhizome, stem, flower, and leaf, etc., of notoginseng are of huge difference ([@B87]). The flower buds of notoginseng contain PPD type saponins predominantly. Nevertheless, both PPD and PPT type saponins are plentiful in roots ([@B107]). HPLC-ELSD and LC-QTOF-MS analysis also revealed the fact that the majority saponins in notoginseng leaves are of PPD types ([@B93]). An UPLC-ESI-MS method combined with principal component analysis (PCA) tentatively gave critical marker compounds in different part of notoginseng for the first time. The marker compounds assigned are listed below: (1) in roots: ginsenoside Rb~1~ and Rg~1~, notoginsenoside A and B, and 20-*O*-glucoginsenoside-Rf; (2) in flower buds: notoginsenoside Q, S and Fc, ginsenoside Rb~2~, Rb~3~, and F~2~; (3) in rhizomes: ginsenoside Re, Rf, Rg~2~, Rc, Rd, Rh~2~ notoginsenoside R~1~, R~4~, Fa and H, and malonyl-ginsenoside-Rb~1~ ([@B11]). It is noteworthy that although most of the naturally existed optical saponins are 20(S)-epimers such as 20(S)-Rg~2~ and 20(S)-Rh~1~, there are still investigations indicating 20(R)-Rg~3~ occurred in raw notoginseng ([@B11]; [@B68]; [@B73]). 20(S)- and 20(R)-Rg~3~ are the only pair of C-20 stereoisomers reported in raw *P. notoginseng*. However, based on our results ([@B67]), only 20(S)-form stereoisomeric saponins could be found in raw *P. notoginseng*. Take 20--80 head raw herbs obtained from Yunnan province as an example, 20(S)-notoginsenoside R~1~, 20(S)-Rg~2~ and 20(S)-Rh~1~ were found, and the amount was in the range of 1.0--1.9, 0.5--1.5, and 0.3--2.1 mg/g, respectively. The structures and locations of saponins existed in raw and processed *P. notoginseng* are summarized in **Figure [1](#F1){ref-type="fig"}** and **Tables [1A](#T1A){ref-type="table"}**,**[B](#T1B){ref-type="table"}**.

###### 

Saponins existed in raw *Panax notoginseng*.

  Structure skeleton   Saponin name                 R1                           R2               R3                            Plant parts                                Reference
  -------------------- ---------------------------- ---------------------------- ---------------- ----------------------------- ------------------------------------------ --------------------------
  A                    Ginsenoside F~2~             -Glc                         /                -Glc                          Roots, rhizome, flower                     [@B11]; [@B87]
  A                    Gypenoside XVII              -Glc                         /                -Glc^6^-^1^Glc                Roots                                      [@B73]
  A                    Notoginsenoside O            -Glc                         /                -Glc^6^-^1^Xyl^3^-^1^Xyl      Leaf, flower                               [@B87]
  A                    Notoginsenoside P            -Glc                         /                -Glc^6^-^1^Xyl^4^-^1^Xyl      Leaf, flower                               [@B87]
  A                    Ginsenoside Rh~2~^∗^         -Glc                         /                -H                            Rhizome                                    [@B11]
  A                    Ginsenoside Rd               -Glc^2^-^1^Glc               /                -Glc                          Roots, rhizome, seed, stem, leaf, flower   [@B87]; [@B112]
  A                    Ginsenoside Rc               -Glc^2^-^1^Glc               /                -Glc^6^-^1^Ara(f)             Roots, rhizome, seed, stem, leaf, flower   [@B87]
  A                    Ginsenoside Ra~2~            -Glc^2^-^1^Glc               /                Glc^6^-^1^Ara(f)^2^-^1^Xyl    Flower                                     [@B87]
  A                    Ginsenoside Rb~2~            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Ara(p)             Roots, rhizome, seed, stem, leaf, flower   [@B87]; [@B112]
  A                    Ginsenoside Ra~1~            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Ara(p)^4^-^1^Xyl   Flower                                     [@B87]
  A                    Ginsenoside Rb~1~            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Glc                Roots, rhizome, seed, stem, leaf, flower   [@B87]
  A                    Ginsenoside Ra~3~            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Xyl^3^-^1^Xyl      Roots, rhizome                             [@B87]; [@B112]
  A                    Ginsenoside Rb~3~            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Xyl                Roots, rhizome, seed, stem, leaf, flower   [@B87]
  A                    20(S)-Ginsenoside Rg~3~      -Glc^2^-^1^Glc               /                -H                            Roots, rhizome, stem, leaf, flower         [@B87]
  A                    Notoginsenoside K            -Glc^6^-^1^Glc               /                -Glc                          Roots, rhizome, seed, stem, leaf, flower   [@B87]
  A                    Notoginsenoside R~4~         -Glc^2^-^1^Glc               /                -Glc^6^-^1^Glc^6^-^1^Xyl      Roots, rhizome                             [@B87]
  A                    Malonyl-ginsenoside Rb~1~    -Glc^2^-^1^Glc^6^-Malonoyl   /                -Glc^6^-^1^Glc                Roots, rhizome                             [@B112]
  A                    Notoginsenoside S            -Glc^2^-^1^Glc^2^-^1^Xyl     /                -Glc^6^-^1^Ara^5^-^1^Xyl      Flower                                     [@B87]; [@B107]
  A                    Notoginsenoside Fa           -Glc^2^-^1^Glc^2^-^1^Xyl     /                -Glc^6^-^1^Glc                Roots, rhizome, stem, leaf, flower         [@B87]; [@B112]
  A                    Notoginsenoside Fc           -Glc^2^-^1^Glc^2^-^1^Xyl     /                -Glc^6^-^1^Xyl                Flower                                     [@B87]
  A                    Notoginsenoside Q            -Glc^2^-^1^Glc^2^-^1^Xyl     /                -Glc^6^-^1^Xyl^4^-^1^Xyl      Flower                                     [@B87]; [@B107]
  A                    Notoginsenoside L            -Glc^2^-^1^Xyl               /                -Glc^6^-^1^Glc                Roots, rhizome, seed, stem, leaf, flower   [@B87]
  B                    20(R)-Ginsenoside Rg~3~      -Glc^2^-^1^Glc               /                -H                            Roots, rhizome                             [@B68]; [@B73]
  C                    Ginsenoside F~1~             -H                           /                -Glc                          Roots, rhizome                             [@B87]
  C                    Chikusetsusaponin L~5~       -H                           /                -Glc^6^-^1^Ara(p)^4^-^1^Xyl   Roots, rhizome, stem, leaf, flower         [@B87]
  C                    Notoginsenoside U            -H                           /                -Glc^6^-^1^Glc                Roots                                      [@B80]
  C                    Ginsenoside Rg~1~^∗^         -H                           -Glc             -Glc                          Roots, rhizome, seed, stem, leaf, flower   [@B87]; [@B112]
  C                    Notoginsenoside R~3~         -H                           -Glc             -Glc^6^-^1^Glc                Roots, rhizome                             [@B87]
  C                    Notoginsenoside R~6~         -H                           -Glc             -Glc^6^-^1^αGlc               Roots, rhizome                             [@B87]
  C                    Ginsenoside Rh~1~^∗^         -H                           -Glc             -H                            Roots, rhizome                             [@B87]
  C                    20-*O*-Glucoginsenoside Rf   -H                           -Glc^2^-^1^Glc   -Glc                          Roots, rhizome                             [@B87]
  C                    Ginsenoside Rf               -H                           -Glc^2^-^1^Glc   -H                            Roots, rhizome, stem                       [@B87]
  C                    Notoginsenoside N            -H                           -Glc^4^-^1^Glc   -Glc                          Roots, rhizome                             [@B87]
  C                    Ginsenoside Re               -H                           -Glc^2^-^1^Rha   -Glc                          Roots, rhizome                             [@B87]; [@B112]
  C                    Ginsenoside Rg~2~^∗^         -H                           -Glc^2^-^1^Rha   -H                            Roots, rhizome, seed, stem                 [@B87]; [@B107]; [@B112]
  C                    Notoginsenoside R~1~         -H                           -Glc^2^-^1^Xyl   -Glc                          Roots, rhizome, seed, stem, leaf, flower   [@B87]; [@B112]
  C                    Notoginsenoside R~2~         -H                           -Glc^2^-^1^Xyl   -H                            Roots, rhizome                             [@B87]
  I                    Notoginsenoside E            -Glc^2^-^1^Glc               /                -Glc                          Roots, rhizome                             [@B87]
  I                    Notoginsenoside A            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Glc                Roots, rhizome                             [@B87]
  I                    Yesanchinoside H             -Glc^2^-^1^Glc               /                -Glc^6^-^1^Xyl                Roots, rhizome                             [@B87]
  J                    Notoginsenoside I            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Glc                Roots, rhizome                             [@B87]
  K                    Notoginsenoside B            -Glc^2^-^1^Glc               /                -Glc^6^-^1^Glc                Roots                                      [@B11]
  L                    Notoginsenoside G            -Glc^2^-^1^Glc               /                -Glc                          Roots, rhizome                             [@B87]
                                                                                                                                                                           

∗

Optical conformation not defined.

###### 

Saponins produced in processed *Panax notoginseng*.

  Structure skeleton   Saponin name                                 R1                     R2                         R3     Reference
  -------------------- -------------------------------------------- ---------------------- -------------------------- ------ ----------------
  A                    20(S)-Ginsenoside Rh~2~                      -Glc                   /                          -H     [@B3]
  A                    20(S)-Ginsenoside Rg~3~                      -Glc^2^-^1^Glc         /                          -H     [@B35]; [@B90]
  A                    20(S)-Ginsenoside Rs~3~                      -Glc^2^-^1^Glc^6^-Ac   /                          -H     [@B3]
  A                    6"-*O*-Acetylginsenoside Rg~3~               -Glc^2^-^1^Glc^6^-Ac   /                          -Glc   [@B43]
  B                    20(R)-Ginsenoside Rh~2~                      -Glc                   /                          -H     [@B3]
  B                    20(R)-Ginsenoside Rg~3~                      -Glc^2^-^1^Glc         /                          -H     [@B35]; [@B90]
  C                    20(S)-Ginsenoside Rh~1~                      -H                     -Glc                       -H     [@B90]
  C                    Koryoginsenoside-R~1~                        -H                     -Glc^6^-(*E*)-2-Butenoyl   -Glc   [@B43]
  C                    Yesanchinoside D                             -H                     -Glc^6^-Ac                 -Glc   [@B43]
  C                    20(S)-Ginsenoside Rg~2~                      -H                     -Glc^2^-^1^Rha             -H     [@B3]
  C                    20(S)-Protopanaxatriol                       -H                     -H                         -H     [@B43]
  D                    20(R)-Ginsenoside Rh~1~                      -H                     -Glc                       -H     [@B35]; [@B90]
  D                    20(R)-Ginsenoside Rg~2~                      -H                     -Glc^2^-^1^Rha             -H     [@B3]
  D                    20(R)-Protopanaxatriol                       -H                     -H                         -H     [@B43]
  E                    Gingsenoside RK~1~                           -Glc^2^-^1^Glc         /                          /      [@B35]; [@B90]
  E                    Gingsenoside Rs~5~                           -Glc^2^-^1^Glc^6^-Ac   /                          /      [@B3]
  F                    Ginsenoside Rg~5~                            -Glc^2^-^1^Glc         /                          /      [@B35]; [@B90]
  F                    Ginsenoside Rs~4~                            -Glc^2^-^1^Glc^6^-Ac   /                          /      [@B3]
  G                    Gingsenoside RK~3~                           -H                     -Glc                       /      [@B35]; [@B90]
  G                    Gingsenoside Rg~6~                           -H                     -Glc^2^-^1^Rha             /      [@B3]
  G                    3β,6α,12β-Trihydroxydammar-20(21),24-diene   -H                     -H                         /      [@B43]
  H                    Ginsenoside Rh~4~                            -H                     -Glc                       /      [@B35]; [@B90]
  H                    Ginsenoside F~4~                             -H                     -Glc^2^-^1^Rha             /      [@B3]
  M                    Sanchinoside B~1~                            -H                     -Glc                       /      [@B43]
  N                    25-Hydroxy-20(R)-Rh~1~                       -H                     -Glc                       -H     [@B43]
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The Processing of *P. notoginseng*
----------------------------------

The processing of traditional Chinese medical drug is a national heritage of a Chinese medicinal culture. The purpose of processing can be classified into four points: (1) eliminating or alleviating the toxicity and side effects; (2) changing the medicinal properties; (3) being convenient for formulation and storage; (4) cleaning the medical drug. In the case of *P. notoginseng*, the medicinal properties are altered upon the processing, i.e., baking, steaming, boiling and frying according to literatures and conventional Chinese methods ([@B37], [@B35]; [@B3]; [@B83]; [@B84]; [@B90]). Among those processing procedures, steaming is most frequently used and the procedure of steaming at 100°C for 3 h has been set as the provincial standard for processed notoginseng powder in Yunnan, China, since April 1, 2013. Temperatures of 100°C and 120°C are practically used in the processing according to published literatures.

Saponins Produced in Processed *P. notoginseng*
-----------------------------------------------

With the processing of notoginseng, some originally existed saponins will be degraded, accompanied by the generation of secondary saponins, including quite a number of saponin stereoisomers.

A series of measurements of HPLC-DAD, LC-MS/MS, LC-QTOFMS and NMR, etc., have been performed on the identification of saponins. Although some of the newly generated saponins are regarded as biomarkers for processed notoginseng, not much emphasis has been put on the presence of stereoismeric saponins so far, which is absolutely a very attractive topic.

The research group of [@B37] and [@B35] is by far the first team to investigate the difference of whole chromatograms of raw and steamed *P. notoginseng*. Results showed that with the extending of steaming time from 0 to 9 h in an autoclave at 120°C, the chromatograms of steamed notoginseng exhibited greater difference with that of raw materials. Except ginsenoside Rc, all the rest of known saponins, i.e., notoginsenoside R~1~, ginsenoside Rg~1~, Re, Rb~1~ and Rd were dramatically degraded. The newly occurred saponins include ginsenoside 20(R)-Rh~1~, Rk~3~, Rh~4~, 20(S)-/20(R)-Rg~3~, Rk~1~ and Rg~5~, which are all stereoisomeric saponins without exception.

The increasing content of 4 pairs of stereoisomeric saponins, i.e., 20(S)-/20(R)-Rh~1~, 20(S)-/20(R)-Rg~3~, Rk~3~ and Rh~4~, and RK~1~ and Rg~5~, upon the extending of steaming and baking of notoginseng were reported ([@B90]). Two *trans* C-20 dehydrated dammarane-type saponins, i.e., Rh~4~ and Rg~5~, were found to be of significantly higher contents compared with other 6 stereoisomeric saponins in processed notoginsengs. The contents of the two saponins reached 1% (w/w) after the dry notoginseng was steamed in an autoclave at 120°C for 8 h.

[@B3] firstly introduced the name "biomarker" into steamed notoginseng. Here, the "biomarker" means the compounds only existed in steamed notoginseng or those of quite high content in steamed notoginseng while extremely low content in raw materials. Here, the biomarkers tentatively given in steamed notoginseng include 8 pairs of stereoisomeric saponins, i.e., ginsenoside 20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rh~1~, 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rs~3~, Rg~6~ and F~4~, Rk~3~ and Rh~4~, RK~1~ and Rg~5~, and Rs~5~ and Rs~4~. Besides, ginsenoside 20(S)-/20(R)-Rh~2~ were also detected in steamed notoginseng, with quiet minor concentrations though. The concept of biomarker could be successfully used to differentiate raw and processed notoginseng.

Statically data has indicated that the content of 20(S)-Rg~3~ in steamed notoginseng reaches its maximum after a 6 h steaming in an autoclave at 120°C, and the prolongation of steaming time would not significantly increase the content of 20(S)-Rg~3~ anymore. However, in the case of 20(S)-Rh~2~, the steaming time should be extended to 24 h for the achievement of its maximum content ([@B84]). The structures of saponins newly generated in raw *P. notoginseng* are also summarized in **Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1A){ref-type="table"}**. In summary, there are one pair C-20 stereoisomers, i.e., 20(S)-/20(R)-Rg~3~, in raw notoginseng, and ten pairs of C-20 stereoisomers, including 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rh~2~, 20(S)-/20(R)-Rh~1~, 20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rs~3~, RK~2~/Rh~3~, Rg~6~/F~4~, Rk~3~/Rh~4~, RK~1~/Rg~5~, and Rs~5~/Rs~4~ reported in processed *P. notoginseng*.

The mechanism of saponin transformations into sapogenins/prosapogenins in the steaming process has been extrapolated from the chemical structures of saponins, especially the changes in their sugar moieties. Under the steaming condition, the hydrolysis of the xylosyl residue attached to C-6 of notoginsenoside R~1~ and the hydrolysis of the rhamnosyl residue at C-6 of ginsenoside Re form ginsenoside Rg~1~. Ginsenoside Rb~1~ is hydrolyzed at the glucosyl residue at C-20 to yield ginsenoside Rd. Rg~1~ and Rd are likely to be the parent compounds of newly formed saponins. The further hydrolysis of the glucosyl residue at C-20 of Rg~1~ yields Rh~1~ which then forms Rh~4~ and Rk~3~ through dehydration at C-20. Similarly, the hydrolysation of the glucosyl residue at C-20 of Rd produces Rg~3~, and dehydration of Rg~3~ at C-20 yields Rg~5~ and Rk~1~, which are shown in **Figure [2](#F2){ref-type="fig"}** ([@B90]).

![Proposed transformation of saponins in the process of steaming of notoginseng. Adopted from [@B90].](fphar-09-00188-g002){#F2}

Determination Strategy for Saponin Stereoisomers
------------------------------------------------

As we all know, 20(S)- and 20(R)-ginsenoside epimers bear very similar molecular structures, and their fragment ions in mass spectra are the same. Recently, [@B68] developed a LC-TOF-MS method to differentiate 20(S)- from 20(R)-ginsenoside epimers based on the mass spectra in positive ion mode. In their study, a slight difference in the peak ratio of \[M-2H~2~O+H\]^+^ to \[M-H~2~O+H\]^+^ has been found in these two epimers. Since the steric hindrance of 20(R)-epimer is greater than that of 20(S)-epimer during the dehydration at the C-20 hydroxyl group, the \[M-2H~2~O+H\]^+^/\[M-H~2~O+H\]^+^ ratio is higher for 20(S)-epimer (1:1) compared with 20(R)-epimer (0.7:1). As the chemical features of 20(S)- and 20(R)-epimers are very close, the retention times of these two epimers might be overlapped according to the separation chromatographic columns. This identification method is of particular importance to distinguish 20(S)- from 20(R)-ginsenoside epimers.

One-dimensional and two-dimensional Nuclear Magnetic Resonance (NMR) spectroscopy is a very useful technique to distinguish the structures of stereoisomers of saponins. Specifically, ^13^C-NMR spectral data can provide information for structural elucidation of ginsenoside isomers. The chemical shifts of the characteristic peaks of 20(S)- and 20(R)- ginsenosides provide information for the identification of stereoisomers. In particular, the changes in chemical shift between 20(S)- and 20(R)-epimers at C-17, C-21 and C-22 in the ^13^C-NMR spectra are approximately Δδ (δ*~S~*-- δ*~R~*) +4.1 ± 0.1, +4.3 ± 0.1, and --7.4 ± 0.0 ppm (**Table [2](#T2){ref-type="table"}**) ([@B104]).

###### 

^13^C-NMR spectroscopicdata for compounds 20(S)-/(R)-Rg~3~, 20(S)-/(R)-Rh~2~, 20(S-)/(R)-Rh~1~, 20(S)-/(R)-Rg~2~ in pyridine-d5.

  No.                                            20(S)-Rg~3~^a^                                  20(R)-Rg~3~^a^   20(S)-Rh~2~^b^   20(R)-Rh~2~^b^   No.       20(S)-Rh~1~^a^   20(R)-Rh~1~^a^   20(S)-Rg~2~^a^   20(R)-Rg~2~^b^
  ---------------------------------------------- ----------------------------------------------- ---------------- ---------------- ---------------- --------- ---------------- ---------------- ---------------- ----------------
  1                                              39.1 t                                          39.1 t           39.1 t           39.1 t           1         39.3 t           39.3 t           39.5 t           39.6 t
  2                                              26.7 t                                          26.6 t           26.7 t           26.6 t           2         27.8 t           27.9 t           27.7 t           27.7 t
  3                                              88.9 d                                          88.9 d           88.7 d           88.7 d           3         78.5 d           78.5 d           78.3 d           78.5 d
  4                                              39.6 s                                          39.6 s           39.6 s           39.6 s           4         40.3 s           40.3 s           41.1 s           39.9 s
  5                                              56.3 d                                          56.3 d           56.3 d           56.3 d           5         61.4 d           61.4 d           60.7 d           60.8 d
  6                                              18.4 t                                          18.4 t           18.4 t           18.4 t           6         80.0 d           80.0 d           74.2 d           74.3 d
  7                                              35.1 t                                          35.1 t           35.1 t           35.1 t           7         45.2 t           45.1 t           46.0 t           46.0 t
  8                                              39.9 s                                          40.0 s           40.0 s           40.0 s           8         41.0 s           41.1 s           41.1 s           41.1 s
  9                                              50.3 d                                          50.3 d           50.3 d           50.3 d           9         50.1 d           50.1 d           49.7 d           49.7 d
  10                                             36.8 s                                          36.9 s           36.9 s           36.9 s           10        39.6 s           39.6 s           39.9 s           39.9 s
  11                                             31.3 t                                          31.4 t           31.3 t           31.4 t           11        32.0 t           32.2 t           32.0 t           32.1 t
  12                                             70.9 d                                          70.8 d           70.9 d           70.8 d           12        71.0 d           70.9 d           71.0 d           70.9 d
  13                                             48.5 d                                          49.2 d           48.5 d           49.2 d           13        48.2 d           48.8 d           48.1 d           48.8 d
  14                                             51.6 s                                          51.7 s           51.7 s           51.7 s           14        51.6 s           51.7 s           51.6 s           51.7 s
  15                                             32.0 t                                          32.1 t           32.0 t           32.1 t           15        31.2 t           31.3 t           31.2 t           31.3 t
  16                                             26.8 t                                          26.7 t           26.8 t           26.7 t           16        26.7 t           26.6 t           26.8 t           26.6 t
  **17**                                         **54.7 d**                                      **50.6 d**       **54.7 d**       **50.6 d**       **17**    **54.7 d**       **50.5 d**       **54.6 d**       **50.5 d**
  18                                             15.8 q                                          15.8 q           16.3 q           16.3 q           18        17.3 q           17.3 q           17.6 q           17.6 q
  19                                             16.3 q                                          16.3 q           15.8 q           15.8 q           19        17.6 q           17.6 q           17.5 q           17.5 q
  20                                             72.9 s                                          72.9 s           72.9 s           72.9 s           20        72.9 s           73.0 s           72.9 s           72.9 s
  **21**                                         **27.0 q**                                      **22.7 q**       **27.0 q**       **22.7 q**       **21**    **26.9 q**       **22.7 q**       **27.0 q**       **22.7 q**
  **22**                                         **35.8 t**                                      **43.2 t**       **35.8 t**       **43.2 t**       **22**    **35.8 t**       **43.2 t**       **35.7 t**       **43.2 t**
  23                                             23.0 t                                          22.5 t           22.9 t           22.6 t           23        22.9 t           22.5 t           22.9 t           22.5 t
  24                                             126.2 d                                         126.0 d          126.3 d          126.0 d          24        126.2 d          126.0 d          126.3 d          126.0 d
  25                                             130.7 s                                         130.7 s          130.7 s          130.7 s          25        130.7 s          130.7 s          130.7 s          130.7 s
  26                                             25.7 q                                          25.8 q           25.8 q           25.8 q           26        25.7 q           25.8 q           25.8 q           25.8 q
  27                                             17.0 q                                          17.2 q           17.6 q           17.7 q           27        17.6 q           17.6 q           17.6 q           17.6 q
  28                                             28.1 q                                          28.1 q           28.1 q           28.1 q           28        31.6 q           31.7 q           32.1 q           32.1 q
  29                                             16.5 q                                          16.5 q           16.7 q           16.7 q           29        16.3 q           16.3 q           16.8 q           17.2 q
  30                                             17.6 q                                          17.6 q           17.0 q           17.3 q           30        16.7 q           17.0 q           17.1 q           17.1 q
                                                                                                                                                                                                                 
  **3-*O*-β -[D]{.smallcaps}-Glucopyranosyl**    **6-*O*-α -[C]{.smallcaps}-Rhamnopyranosyl**                                                                                                                    
                                                                                                                                                                                                                 
  1′                                             105.0 d                                         105.1 d          106.9 d          106.9 d          1′        106.0 d          106.0 d          101.9 d          101.9 d
  2′                                             83.4 d                                          83.4 d           75.7 d           75.7 d           2′        75.4 d           75.4 d           79.4 d           79.4 d
  3′                                             77.9 d                                          77.9 d           78.7 d           78.7 d           3′        79.6 d           79.6 d           78.5 d           78.5 d
  4′                                             71.6 d                                          71.6 d           71.8 d           71.8 d           4′        71.8 d           71.8 d           72.4 d           72.4 d
  5′                                             78.2 d                                          78.2 d           78.3 d           78.3 d           5′        78.1 d           78.1 d           78.3 d           78.3 d
  6′                                             62.8 t                                          62.8 t           63.0 t           63.0 t           6′        63.0 t           63.0 t           63.0 t           63.1 t
                                                                                                                                                                                                                 
  **2′-*O*-β -[D]{.smallcaps}-Glucopyranosyl**   **2′-*O*-α -[C]{.smallcaps}-Rhamnopyranosyl**                                                                                                                   
                                                                                                                                                                                                                 
  1″                                             106.0 d                                         106.0 d                                            1″                                          101.7 d          101.7 d
  2″                                             77.1 d                                          77.1 d                                             2″                                          72.2 d           72.2 d
  3″                                             78.3 d                                          78.3 d                                             3″                                          72.5 d           72.6 d
  4″                                             71.6 d                                          71.6 d                                             4″                                          74.1 d           74.1 d
  5″                                             78.0 d                                          78.1 d                                             5″                                          69.4 d           69.4 d
  6″                                             62.7 t                                          62.7 t                                             6″                                          18.7 q           18.7 q
  COCH~3~                                                                                                                                           COCH~3~                                                      
  COCH~3~                                                                                                                                           COCH~3~                                                      
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-NMR data determined by distortionless enhancement by polarization transfer (DEPT) experiments.
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-NMR data of this compound was measured at 125 MHz and
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-NMR data of this compound was measured at 150 MHz. The bold values are the
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c

-NMR spectra of C-17, C-21 and C-22 that particularly change in chemical shift between 20(S)- and 20(R)-epimers.

The letters "t, d, s, q" means triplet peak, double peak, single peak and quadruple peak respectively.

High Performance Liquid Chromatography (HPLC) is the most frequently employed separation method for the analysis of saponins stereoisomers. HPLC can be combined with different detection techniques such as ultraviolet detector (UV), diode array detection (DAD), evaporative light scattering detector (ELSD), mass spectrometry detector (MS) and charged aerosol detector (CAD). There are two main difficulties that researchers come across in performing HPLC-UV or HPLC-DAD analysis of saponin stereoisomers. Firstly, owing to their very similar structures, saponin stereoisomers could not be baseline separated on a simple isocratic eluted chromatographic condition by an ordinary reversed-phase C18 column. A chromatographic method with gradient elution program is often necessary, and the parameters of the appropriate chromatographic column, e.g., packing material, particle size, length, etc., should be selected elaborately; Secondly, since saponins don't possess aromatic groups, their UV absorptions are very low. Thus, only end absorption at around 200 nm could be chosen for UV or DAD detection. Therefore, ELSD, a universal and non-specific analytical detector, has been widely used in the detection of natural compounds including saponins. Firstly introduced in 2002, CAD, another universal detector for non-volatile and semi-volatile compounds, has been used in the detection of saponins in notoginseng. Moreover, MS and tandem MS detector are often used when the elucidation of saponin structures is needed, or when very high sensitivity for the detection of analytes is required. MS detector is particularly important in the detection of saponins in biological matrices.

Gradient elution of water and acetonitrile has been regarded as the most widely used chromatographic conditions for HPLC-UV or DAD separation of saponin stereoisomers, since acetonitrile has a fairly strong eluting power and its cut-off wavelength is lower than 200 nm, which makes it suitable for the detection at end absorption ([@B95]; [@B49]; [@B12]; [@B61]). In this case, UV wavelength is normally set at 203 nm for saponin determination. For ELSD and MS detectors, CH~3~COOH and HCOOH are usually added into mobile phases to assist a better volatilization of saponin analytes ([@B3]; [@B78]; [@B2]; [@B88]). Our group has developed a HPLC-CAD method to simultaneously separate 22 saponins existed in raw and processed notoginseng, in which 5 pairs of 20(S)- and 20(R)-ginsenoside epimers were separated ([@B67]). In addition, using an appropriate column with small particle size can gain higher efficiency and better isolation. Ultra-performance liquid chromatography (UPLC), which utilizes silica particles of less than 2 μm, makes it possible to perform better separations in short periods of time ([@B3]; [@B61]). The chromatographic conditions for simultaneous determination of stereoisomeric saponins are summarized in **Table [3](#T3){ref-type="table"}**.

###### 

Chromatographic conditions for simultaneous determination of stereoisomeric saponins.

  Column                                           Mobile phase                                                                          Detector                                                        Stereoisomeric saponins simultaneously separated                                                                                         Reference
  ------------------------------------------------ ------------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -----------
  Zorbax Eclipse XDB-C18 (25 cm × 4.6 mm, 5 μm)    A: H~2~O, B: CH~3~CN; gradient elution                                                UV, 203 nm                                                      20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rh~1~, 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rh~2~, Rk~1~/Rg~5~, Rg~6~/F~4~, Rk~3~/Rh~4~, 20(S)-/20(R)-PPD   [@B12]
  Discovery C18 (25 cm × 4.6 mm, 5 μm)             A: H~2~O, B: CH~3~CN; gradient elution                                                UV, 203 nm                                                      20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rh~2~, 20(S)-/20(R)-PPD                                                                                 [@B49]
  ACQUITY BEH C18 (10 cm × 2.1 mm, 1.7 μm)         A: 0.001% H~3~PO~4~, B: 0.001% H~3~PO~4~ in CH~3~CN; gradient elution                 DAD, 203 nm                                                     20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rh~2~, Rk~1~/Rg~5~, Rg~6~/F~4~, Rk~3~/Rh~4~, RK~2~/Rh~3~                            [@B61]
  Waters HSS C18 column (25 cm × 4.6 mm, 3.5 μm)   A: H~2~O, B: CH~3~CN; gradient elution                                                CAD; UV 203 nm                                                  20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rh~1~, 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rh~2~, 20(S)-/20(R)-PPD                                         [@B67]
  Zorbax Eclipse XDB-C18 (25 cm × 4.6 mm, 5 μm)    A: H~2~O, B: CH~3~CN; gradient elution                                                UV 203 nm                                                       20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rs~3~, Rk~1~/Rg~5~, Rg~6~/F~4~, RS~4~/Rh~5~                                         [@B95]
  Discovery C18 (25 cm × 4.6 mm, 5 μm)             A: CH~3~CN-H~2~O-5% CH~3~COOH (10:85:5), B: CH~3~CN-H~2~O (80:20); gradient elution   ELSD; probe temperature: 60°C; nebulizer flow: N~2~ 1.8 L/min   20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rs~3~, Rg~6~/F~4~, Rk~3~/Rh~4~, Rk~1~/Rg~5~, RS~4~/Rh~5~                                                [@B78]
  ACQUITY C18 (10 cm × 2.1 mm, 1.7 μm)             A: 0.001% HCOOH, B: 0.001% HCOOH in CH~3~CN; gradient elution                         TOF MS, ES+ and ES- mode                                        20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rh~1~, 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rs~3~, F~4~/Rg~6~, Rk~3~/Rh~4~, RK~1~/Rg~5~, Rs~5~/ Rs~4~       [@B3]
  Zorbax Extend C18 (25 cm × 4.6 mm, 5 μm)         A: 0.001% HCOOH, B: 0.001% HCOOH in CH~3~CN; gradient elution                         QTOF MS, ESI- mode                                              20(S)-/20(R)-Rg~2~, 20(S)-/20(R)-Rh~1~, 20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rh~2~, F~4~/Rg~6~, RK~1~/Rg~5~                                  [@B88]
  Acclaim RSLC C18 (15 cm × 2.1 mm, 2.2 μm)        A: CH~3~CN, B: 0.1% HCOOH; gradient elution                                           Tandem MS, ES- mode                                             20(S)-/20(R)-Rg~3~, 20(S)-/20(R)-Rh~2~                                                                                                   [@B2]
                                                                                                                                                                                                                                                                                                                                                  

Preparation of Saponin Stereoisomers
------------------------------------

As far as we know, major ginsenosides, e.g., Rb~1~, Rb~2~, Rd, Re, and Rg~1~, occupy 90% of total saponins which exist naturally in raw herbs. However, minor saponins, e.g., Rg~3~, Rh~2~, Rg~2~, Rh~1~, and F~1~, usually exert stronger pharmacological activities such as anti-tumor, antidiabetic, anti-oxidative, and anti-aging effects over the glycosylated major saponins ([@B6]; [@B31]). A variety of technologies has been performed to produce minor saponins, and the processes include mild acid hydrolysis, alkali treatment and microbial conversions ([@B1]; [@B5]; [@B10]). Ginsenoside Rb~1~, Rb~2~, Rc and Rd can be converted into a mixture of 20(S)- and 20(R)-Rg~3~ by either mild acid treatment or heating ([@B62]). Nevertheless, side-reactions such as epimerization, hydration and hydroxylation are the disadvantages of chemical hydrolysis. Moreover, the optical purification from the mixture of 20(S)- and 20(R)-ginsenoside mixture is a time-consuming task. Fortunately, microorganic and enzymatic hydrolysis from major saponins has been found to be stereoselective and regarded as an efficient technology to avoid those side-reactions mentioned above ([@B49]). Another advantage of this method is that the 20(S)-epimer produced would not transform to their 20(R)-epimer during the course of the reaction. Aspergillus niger obtained from soil shows a strong and stereoselective ability to transform Rg~3~(S, R) into PPD(S, R) completely. Microbacterium sp. GS514 isolated and identified from soil of a ginseng field exhibits a strong capability to convert ginsenoside Rb~1~ to 20(S)-Rg~3~ ([@B5]). A new ginsenoside-transforming-glucosidase (BglQM) from *Mucilaginibacter* sp. Strain QM49 efficiently transforms ginsenoside Re and Rg~1~ into 20(S)-Rg~2~ and 20(S)-Rh~1~, respectively ([@B9]). Moreover, [@B13] reported a method to transform Re to 20(S)-Rg~2~ with the aid of Pseudonocardia sp. Gsoil 1536, which can produce high-purity 20(S)-Rg~2~ in a 100 g scale. Various saponin-hydrolyzing pathways to produce stereoisomeric saponins from major saponins by enzymatic hydrolysis are summarized in **Table [4](#T4){ref-type="table"}** for practical application.

###### 

Major saponins stereoisomers transformations by glycoside hydrolases.

  Name of glycoside hydrolase   Microorganism                            Saponin conversion pathway                                                       Reference
  ----------------------------- ---------------------------------------- -------------------------------------------------------------------------------- -----------
  GS514                         *Microbacterium* sp.                     Rb~1~→Rd→Rg~3~(S)                                                                [@B5]
  Glycosidase                   *Aspergillus niger*                      Rf→Rh~1~(S)→PPT(S)                                                               [@B48]
                                                                         Rg~3~(S)→Rh~2~(S)→PPD(S); Rg~3~(R)→Rh~2~(R)→PPD(R)                               [@B49]
  Ginsenosidase type IV         *Aspergillus* sp. 39 g strain            Rg~1~/Re→Rh~1~(S)→PPT(S); Rf(S)/Rg~2~(S)→Rh~1~(S)→PPT(S)                         [@B91]
  Ginsenosidase type III        *Terrabacter ginsenosidimutans* sp.      Rg~3~(S)→Rh~2~(S)→PPD(S)                                                         [@B20]
  BglSk                         *Sanguibacter keddieii*                  Rg~3~(S)→Rh~2~(S)→PPD; Re→Rg~2~(S); Rb~1~→Rd→Rg~3~(S)                            [@B27]
  Bgp1                          *Microbacterium esteraromaticum*         Rb~1~→Rd→Rg~3~(S)                                                                [@B70]
  BglAm                         *Actinosynnema mirum*                    Rd→F~2~→Rh~2~(S); Rg~3~(S)→Rh~2~(S)→PPD(S); Re→Rg~2~(S); Rg~1~→Rh~1~(S)→PPT(S)   [@B8]
  BglQM                         *Mucilaginibacter* sp. strain QM49       Re→Rg~2~(S); Rg~1~→Rh~1~(S); Rb~1~→Rd→Rg~3~(S)                                   [@B9]
  BglPC28                       *Pseudonocardia* sp. strain Gsoil 1536   Re→Rg~2~(S); Rg~1~→Rh~1~(S); Rb~3~→Rg~3~(S); Rb~1~→Rg~3~(S); Rd→Rg~3~(S)         [@B13]
                                                                                                                                                          

Pharmacology
============

Pharmacological Difference Between Raw and Processed *P. notoginseng*
---------------------------------------------------------------------

In traditional Chinese medical applications, processed notoginseng is distinguished from raw notoginseng by the claim of its capability to "nourish" blood ([@B53]). So far, not many contemporary researches have been performed to focus on the pharmacological difference between these two types of herbs, however, some research reports have still revealed that processed notoginseng exhibit more potent pharmaceutical activities than raw notoginseng, such as anticancer, antiplatelet and anticoagulant, and platelet aggregation inhibition effects, etc.

Compared with raw *P. notoginseng*, steamed *P. notoginseng* is found to be more potent in antiplatelet and anticoagulant effects *in vitro*. Moreover, it also exhibites stronger platelet aggregation inhibition effects *ex vivo*, and the effects could be enhanced along with the prolongation of steaming duration ([@B36]). A colorimetric WST-1 assay has been performed to evaluate the anti-proliferative effects of raw and steamed *P. notoginseng* on three human liver cancer cells, i.e., SNU449, SNU182 and HepG2. Results have indicated that steamed *P. notoginseng* presents higher anti-proliferative effects against these three types of liver cancer cells. Besides, the anti-proliferative effects of 5 originally existed saponins in raw *P. notoginseng*, i.e., Rg~1~, Rb~1~, Rd, Re and R~1~, as well as 4 newly produced saponins in steamed *P. notoginseng*, i.e., Rh~2~, Rk~1~, Rk~3~ and 20(S)-Rg~3~ have also been assessed. Not surprisingly, Rk~3~, Rh~2~, Rk~1~ and 20(S)-Rg~3~ exhibits more anti-proliferative effects compared with the original saponins ([@B85]). Moreover, the extract of steamed notoginseng is effective in the inhibition of proliferation of SW-480 human colorectal cancer cells. Meanwhile, the comparison results of the proliferation effects between ginsenoside Rg~1~, Rb~1~ and Rg~3~ shows that the newly generated ginsenoside Rg~3~ is the most potent saponin on the antiproliferative activities on SW-480 human colorectal cancer cells ([@B83]). This anticancer effect of steamed *P. notoginseng* was further confirmed by MTS method and flow cytometry ([@B82]).

Apparently, the difference of compound basis between raw and processed *P. notoginseng* directly influences their pharmacological activities. With the prolongation of processing duration, quite a few secondary saponins which are not naturally occurred in raw herbs are gradually generated in *P. notoginseng*. What should be emphasized is that most of the newly occurred saponins are stereoisomers, which exhibit quite potent biological activities. That explains why processed *P. notoginseng* exhibit distinct pharmacological behaviors compared with raw herbs.

Stereospecific Pharmacological Effects of 20(S)- and 20(R)-Rg~3~
----------------------------------------------------------------

Ginsenoside Rg~3~ is one of the most biologically potent saponins in *P. notoginseng*, which exerts a wide scope of pharmacological actions, e.g., anti-inflammatory ([@B65]), anti-tumor ([@B30]), antioxidant ([@B97]), anti-diabetic ([@B21]; [@B29]), and neuroprotective ([@B38]) activities. Extensive research have revealed that ginsenoside Rg~3~ displays a wide spectrum of anticancer activities in the treatment of colon, lung ([@B30]), breast ([@B24]), hepatic ([@B41]), pancreatic ([@B16]) cancer and melanoma ([@B74]), via the mechanism of promoting cancer cell apoptosis, as well as inhibiting cell proliferation, metastasis and invasion. In addition, ginsenoside Rg~3~ has also been demonstrated to be a beneficial supplement in the enhancement of the inhibitory effects on chemotherapy ([@B79]).

At the early stages of pharmacological researches on this ginsenoside, the optical conformation was not specified, and the mixture of 20(S)- and 20(R)-Rg~3~ epimers has often been studied since very little information was obtained on their stereoselective differences in pharmacological actions ([@B6]). However, recent investigations have revealed that this pair of ginsenoside Rg~3~ stereoisomers exhibits a diversity of stereoselective activities, such as relaxation of coronary artery contractions, regulation of ion channel, effects on immune system, as well as anti-tumor, neuro-protective, anti-oxidant and antidiabetic activities, based on the chiral center at C-20 in their molecular structures.

### Effects on Cardiovascular System

Ginsenoside Rg~3~ has potent pharmacological activities in cardiovascular systems. Stereospecific activities of Rg~3~ epimers have been discovered on coronary artery relaxation, endothelial cells survival, and platelet anti-aggregation, etc.

Investigations on swine coronary artery have revealed that 20(S)-Rg~3~, but not 20(R)-Rg~3~, engenders an effective coronary artery relaxation induced by 25mM KCl, which is concentration dependent yet endothelium independent. Moreover, although both Rg~3~ epimers could induce a significant, concentration-dependent relaxation of coronary artery contractions in intact samples induced by 3 mM 5-HT, only 20(S)-Rg~3~ inhibits coronary artery contraction in endothelium-denuded arteries. The stereospecific effects are probably owing to the inhibition of L-type Ca^2+^ channel or the elevation of Ca^2+^ level in the cells induced by 5-HT receptors ([@B26]). 20(S)-Rg~3~ has been found to show anti-apoptotic activity in human endothelial cells through Akt-dependent inhibition of the mitochondrial apoptotic signaling pathway. 20(S)-Rg~3~ has been shown to be comparable to 20 ng/ml of vascular endothelial growth factor (VEFG) on the promotion ability of endothelial cells survival, however, 20(R)-Rg~3~ only exhibits very little activity ([@B55]). Moreover, [@B40] investigated the anti-platelet aggregation activities of Rg~3~ epimers, and results showed that 20(S)-Rg~3~ strongly inhibited arachidonic acid-induced platelet aggregation, while 20(R)-Rg~3~ inhibited collagen-induced platelet aggregation.

### Anti-tumor Effects

Quite a few researches have indicated that both 20(S)- and 20(R)-Rg~3~ exhibit anti-tumor activities, which have received much attention in recent investigations. Nevertheless, it is hard to say which stereoisomer exhibit higher anti-tumor activities based on available literatures so far, as these two compounds may function differently in different cell lines.

20(S)-Rg~3~ stereospecifically induces angiogenesis by promoting human endothelial cells proliferation, migration and tube formation *in vitro*, and endothelial sprouting *ex vivo* at a micromolar concentration level ([@B34]). It is identified to be the main active component with anticancer effects on human gastric cancer AGS cells, while 20(R)-Rg~3~ has no effect ([@B60]). Moreover, 20(S)-Rg~3~ is also found to be effective in other cell lines, such as human leukemic U937 and HL-60 cells ([@B69]), multiple myeloma U266 cells ([@B76]), human ovarian cancer HO-8910 ([@B92]) and A2780 cells ([@B63]), and colon cancer HT-29 cells ([@B108]).

However, 20(R)-Rg~3~ shows a stronger anti-tumor effect on the inhibition of H22 transplanted tumors growth, as well as a higher immunomodulatory activity on H22-bearing mice, compared with its 20(S)-epimer, which may be attributed to its ability to stimulate lymphocyte proliferation and elevate cytokine levels in tumor-bearing mice ([@B99]). Furthermore, the comparison of the effects between 20(S)- and 20(R)-Rg~3~ on epithelial-mesenchymal transition (EMT) reveal that 20(R)-Rg~3~, but not 20(S)-Rg~3~, markedly increases the expression of the epithelial marker *E*-cadherin and represses Snail upregulation and the expression of the mesenchymal marker vimentin during the initiation of the TGF-β1-induced EMT. 20(R)-Rg~3~ also inhibits the TGF-β1-induced increasing in cell migration, invasion, and anoikis resistance of A549 lung cancer cells ([@B30]).

### Effects on Ion Channel Current

20(S)- and 20(R)-Rg~3~ epimers are reported to exhibit stereospecific actions in ion channels, including Ca^2+^, K^+^, and Na^+^ ([@B22]; [@B39]). Without exception, 20(S)-Rg~3~, but not 20(R)-Rg~3~, has been demonstrated to significantly inhibit these channel currents in a dose- and voltage-dependent manner. The ^1^H and ^13^C NMR chemical shifts of all hydroxyl protons and the conformation of the tertiary structures of 20(S)- and 20(R)-Rg~3~ epimers indicates that a more potent interaction might be occurred between 20(S)-Rg~3~ with the receptor sections in ion channels compared with 20(R)-Rg~3~, probably due to the deduction that the hydroxyl group of 20(S)-Rg~3~ on C-20 may be geometrically better disposed to the hydroxyl receptor region in those ion channels. Moreover, 20(S)-Rg~3~ is more efficient on the regulation of mutant 5-HT3A receptor channel activity ([@B39]). It can be inferred that 20(S)-Rg~3~ might be a useful agent for regulation of ion channel current, which could be used for the treatment of coronary artery and neuron system disease. For instance, the neuro-protection mechanism and antinociceptive effects on inflammation of 20(S)-Rg~3~ is via the mechanism of regulating channels and receptors ([@B65]; [@B23]).

### Effects on Immune System

Several studies have highlighted the stereospecific effects of ginsenoside Rg~3~ in immune system. [@B96] utilized ovalbumin (OVA) as a model to assess the adjuvant effects of 20(S)-/20(R)-Rg~3~ epimers. Results showed that 20(R)-Rg~3~ exhibit higher adjuvant effects on OVA induced immune system in mice. Another study has compared the effects of these two epimers on the growth of hepatocellular carcinoma H22 transplanted tumors and the immune function of H22-bearing mice. And 20(R)-Rg~3~ has been found to be stereo-specifically inhibiting H22 tumor growth *in vivo* at least partly by improving the host's cellular immunity, which means that this 20(R)-epimer is clinically more potent in the treatment of immune-mediated diseases ([@B99]). Interestingly, although 20(S)-Rg~3~ exhibits many potent activities in other clinical treatments, 20(R)-Rg~3~ seems to be a better epimer for the treatment of immune disorders based on the literature so far.

### Antidiabetic Effects

To explore the difference of ginsenoside Rg~3~ epimers in antidiabetic effects, glucose-stimulated insulin secretion and phosphorylation of AMPK were examined in HIT-T15 and C2C12 myotubes, respectively. 5 mM of 20(S)-Rg~3~ enhanced insulin secretion to an extent comparable to 5 mM glipizide (58 and 61% increments), but 20(R)-Rg~3~ did not show any significant effect. In C2C12 myotubes, although both of these two epimers significantly promoted the phosphorylations of AMPK and acetyl-CoA carboxylase (ACC), 20(R)-Rg~3~ showed a little less effect. These results indicate that 20(S)-Rg~3~ might be a more potent anti-diabetic agent ([@B64]). The antidiabetic activities of 20(S)-Rg~3~ have further been demonstrated, and the mechanisms on the treatment of diabetic renal damage and type 2 diabetes have been elucidated on this compound ([@B21]).

### Anti-oxidant and Anti-photoaging Effects

20(R)-Rg~3~ has been found to be a more potent antioxidant compound than 20(S)-Rg~3~. 20(R)-Rg~3~ significantly inhibites oxidative stress in mice induced by cyclophosphamide based on the parameters of spleen and thymus, total antioxidant capacity, the activities of catalase, superoxidase dismutase, lysozyme, xanthine oxidase as well as the levels of malondialdehyde and nitric oxide ([@B97]). Nevertheless, 20(S)-Rg~3~, but not 20(R)-Rg~3~, has been investigated to decrease intracellular reaction oxygen species (ROS) levels induced by UV-B in human keratinocyte HaCaT cells and human dermal fibroblast cells, respectively. Moreover, 20(S)-Rg~3~ exhibites UV-B-induced matrix metalloproteinase (MMP)-2 inhibition activities in HaCaT cells, while 20(R)-Rg~3~ does not ([@B44]). Although both 20(S)- and 20(R)-Rg~3~ may exhibit high anti-oxidant activities, the results are not contradictory. The experimental design of different animal models and cell lines may lead to different conclusions based on diverse therapeutic targets. Thus, further researches should be performed to elucidate the underlying mechanisms of these two stereoisomers.

Stereospecific Effects of Other Saponin Stereoisomers
-----------------------------------------------------

Except for ginsenoside Rg~3~, other stereoisomeric saponins have also been found to exhibit stereospecific pharmacological activities. For example, 20(S)-/20(R)-Rh~2~, the metabolites of 20(S)-/20(R)-Rg~3~, have also been studied on the stereospecific effects in their antitumor, anti-photoaging, anti-inflammatory, antioxidative, matrix metalloproteinase inhibitory and osteoclastgenesis inhibitory effects ([@B47]; [@B7]; [@B14]; [@B58]). Compared with 20(R)-Rh~2~, 20(S)-Rh~2~ exhibits stronger anticancer effects on prostate cancer cells and human lung adenocarcinoma A549 cells ([@B46]; [@B109]). Moreover, the inhibitory effects of 20(S)-Rg~2~ on catecholamine secretion are slightly greater than those of 20(R)-Rg~2~ ([@B33]).

These results reveal that the structural difference between saponin stereoisomers may lead to significant distinctions in pharmacological activities, and this phenomenon should be carefully considered in the future development of saponin-based therapeutics. Brief contrast of the pharmacological effects of stereoisomeric saponins with their corresponding stereoisomers is given in **Table [5](#T5){ref-type="table"}**.

###### 

Brief contrast of the pharmacological effects of ginsenoside Rg~2~ and Rh~2~ stereoisomers.

  Name                Stereo-center   Pharmacological effects to be compared                                                                                                       Stereoisomer with more potent activities   Reference
  ------------------- --------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ -----------
  Ginsenoside Rg~2~   20(S)/20(R)     Inhibition of catecholamine secretion                                                                                                        20(S)-Rg~2~                                [@B33]
  Ginsenoside Rh~2~   20(S)/20(R)     Skin anti-photoaging activities                                                                                                              20(S)-Rh~2~                                [@B58]
                                      Inhibition of osteoclastgenesis in RAW264 cells                                                                                              20(R)-Rh~2~                                [@B47]
                                      Inhibition of prostate cancer cells proliferation                                                                                            20(S)-Rh~2~                                [@B46]
                                      Induction of apoptosis in human lungadenocarcinoma A549 cells                                                                                20(S)-Rh~2~                                [@B109]
                                      Anti-inflammatory, antioxidative and matrix metalloproteinase inhibitory activities in the LPS-stimulated murine RAW264.7 macrophage cells   20(R)-Rh~2~                                [@B7]
                                      Inhibiting of erythroleukemia K562 cells proliferation                                                                                       20(S)-Rh~2~                                [@B100]
                                      Inhibition of aldose reductase                                                                                                               20(S)-Rh~2~                                [@B14]
                                                                                                                                                                                                                              

Pharmacological Effects of Other Stereoisomeric Saponins
--------------------------------------------------------

Except for optical saponin epimers, geometric saponin epimers generated after the processing of *P. notoginseng* also exhibit high pharmacological activities, although the stereospecific effects have not been studied. For example, gingsenoside RK~1~ has been proved on its anti-platelet aggregation, anti-tumor, and vascular leakage blocking activities ([@B28]; [@B29]; [@B52]). Gingsenoside Rg~5~, the geometric isomer of RK~1~, is shown to possess anti-inflammatory effects ([@B42]). Moreover, Rg~5~ and Rh~3~ can protect memory deficits induced by scopolamine ([@B25]). Gingsenoside RK~3~ is capable to prevent apoptosis induced by hypoxia-reoxygenation in H9c2 cardiomyocytes ([@B81]).

The potent pharmacological activities of stereoisomeric saponins, which are mostly generated and acting as biomarkers in processed *P. notoginseng*, very well explain the pharmacological differences between the raw and processed herbs. Hence, the pharmacological behaviors of processed *P. notoginseng* are the combination of pharmacological activities of all the secondary saponins, which conforms to the theory of multi component multi targets of traditional Chinese medical drugs.

Mechanism of Stereospecific Properties Between Saponin Stereoisomers
--------------------------------------------------------------------

Based on the above reports, a diversity of pharmacological differences has been discovered in saponin stereoisomers. Unfortunately, very few studies have been investigated on the mechanism of this interesting phenomenon at a molecular level by far. Apparently, the position of the hydroxyl group on C-20 plays an important role on the different activities of stereoisomers of Rg~3~. The structure-activity relationship of 20(S)-/20(R)-Rg~3~ has been investigated on the determination of their difference in NMR spectroscopy and inhibition activities on Na^+^ channel current. The superimposition of 20 structures of 20(S)- and 20(R)-Rg~3~ indicates that the alkene chain of 20(R)-Rg~3~ is more flexible, however, that of 20(S)-Rg~3~ seems to be stable and tightly packed near the aglycon backbone. Moreover, the space filling representations of these two epimer (**Figure [3](#F3){ref-type="fig"}**) showed that the hydroxyl groups of HO12 and HO20 in 20(S)-Rg~3~ are less accessible to water compared with 20(R)-Rg~3~, while those of the latter epimer are found to be exposed to water. Taken together, the alignment of the 20(S)-Rg~3~ to receptor regions in Na^+^ channels is easier, and the hydrogen bonds occurred in 20(S)-Rg~3~ and receptor were more stable ([@B22]).

![**(A)** Hydrogen bonds between HO20 and 012 in 20(S)- and 20(R)-Rg3. **(B)** Space filling representation of 20(S)-Rg~3~. **(C)** Space filling representation of 20(R)-Rg~3~ (adopted from [@B22]).](fphar-09-00188-g003){#F3}

The interaction of 20(S) and 20(R)-Rg~3~ with human serum albumin (HSA) has been investigated using surface-enhanced Raman scattering (SERS) and fluorescence spectroscopy. Results indicate that HSA is prone to bind to glucose ring upon the interaction with Rg~3~, with the aglycon part exposed outside. Thus when the combination of 20(S)- or 20(R)-Rg~3~-HAS complex with targeting binding site occurs, the stereoscopic spatial structures of these two epimers at C-20 may cause different binding affinities and biological activities ([@B110]). Computational modeling has been utilized to elucidate the mechanism of stereospecific activities of 20(S)-Rg~3~ on peroxisome proliferator-activated receptor-gamma (PPARγ). It has been verified that Tyr473 in helix-12 is crucial to full agonistic activity of PPARγ. The docking results reveal that the hydroxyl group at C-20 of 20(S)-Rg~3~ interacts with Tyr473 via hydrogen bond. However, 20(R)-Rg~3~ is not able to interact with Tyr473 optimally due to its sterically strained binding pocket (**Figure [4](#F4){ref-type="fig"}**). It can be inferred that the biological activities difference of 20(S)- and 20(R)-Rg~3~ on PPARγ is due to their different binding affinities according to stereo-structures ([@B34]).

![Docking structures of 20(S)-Rg~3~ and 20(R)-Rg3 in the LBD of PPAR *γ.* The ginsenosides and the side chain of Tyr473 in helix-12 (H-12) are shown in sticks. Crystal structure of rosiglitazone in PPAR γ (PDB:1ZGY) is superimposed and shown in gray for comparison. **(A)** The docked 20(S)-Rg~3~ adopts a position similar of rosiglitazone in the protein and the hydroxyl group at the C20 position interacts with the side chain of Tyr473 (dotted line). **(B)** The docked 20(R)-Rg~3~ occupies similar position as the 20(S)-Rg~3~ in the protein but only the methyl group at the C20 position points toward Tyr473 and does not form any effective hydrogen bond. The protein backbones are rendered as faded out ribbons. Hydrogen atoms are not shown for clarity. Both Rg~3~ stereoisomers were docked into the protein by using Autodock 4.0, while the receptor protein structure is directly obtained from the protein databank (adopted from [@B34]).](fphar-09-00188-g004){#F4}

Pharmacokinetics
================

Saponin stereoisomers are proved to exhibit different pharmacokinetic characteristics including absorption, distribution, and metabolism. [@B2] developed a LC-MS/MS method for simultaneous determination of Rg~3~ and Rh~2~ epimers, and the method was successfully applied to a pharmacokinetic study after oral administration of fermented ginseng extract in rats. 20(S)-epimers of both Rg~3~ and Rh~2~ showed significantly higher plasma concentrations and area under curve (AUC) values compared with their corresponding 20(R)-epimers. It can be inferred that 20(R)-epimers of Rg~3~ and Rh~2~ have lower membrane permeability and poorer absorption. Moreover, the absorption profiles of 20(S)-Rh~2~ was proved to be better than those of 20(R)-Rh~2~, partly because 20(R)-Rh~2~ performs more potent ABC-transporter-mediated efflux ([@B15]). Moreover, Bae et al. found that *Bacteroides* sp., *Eubacterium* sp., and *Bifidobacterium* sp. isolated from human fecal microflora can metabolize Rg~3~ to PPD via Rh~2~, however, *Fusobacterium* sp. is able to metabolize Rg~3~ to Rh~2~. The metabolism speed of 20(S)-Rg~3~ to its 20(S)-metabolites is 19-time higher than that of 20(R)-Rg~3~ ([@B1]). Our group has also found that after a same intravenous dosage of 5 mg/kg in rats, the AUC of 20(S)-Rg~3~ was about 2.3 times greater than that of 20(R)- Rg~3~. The half time of 20(S)-Rg~3~ was much longer and the clearance was lower (**Table [6](#T6){ref-type="table"}**). A single direction chiral inversion of 20(R)-Rg~3~ to 20(S)-Rg~3~ was found in rats both after intravenous and intra-gastric administration. Both Rg~3~ epimers can undergo deglycosylated steps to their corresponding C20 chiral configurations of Rh~2~ and PPD, but the deglycosylation rates and patterns were different (**Figure [5](#F5){ref-type="fig"}**) ([@B66]). The pharmacokinetic studies of stereospecific properties of ginsenoside stereoisomers may provide an experimental basis to explain the different activities of two stereoisomers.

###### 

The main pharmacokinetic parameters of 20(S)-Rg~3~ and 20(R)-Rg~3~ in rat plasma after intravenous and intra-gastric administration.

  Components    Administration Route   Dosage     C~max~              T~max~      AUC (h^∗^ng/ml)    *t*~1/2~(h)
  ------------- ---------------------- ---------- ------------------- ----------- ------------------ -------------
  20(S)-Rg~3~   i.v.                   5 mg/kg    70096.2 ± 7204.6    0.033       39591.8 ± 1800.0   4.7 ± 1.5
  20(R)-Rg~3~   i.v.                   5 mg/kg    46439.2 ± 14365.5   0.033       11919.3 ± 1896.3   1.5 ± 0.4
  20(S)-Rg~3~   i.g.                   50 mg/kg   98.1 ± 40.5         5.7 ± 2.0   672.1 ± 308.1      2.2 ± 0.4
                                                                                                     

Adopted from

Peng et al. (2016a)

.

![Plasma concentration-time curves of 20(S)- and 20(R)-ginsenoside Rg3 and their corresponding detectable chiral metabolites after iv administration of 20(S)-Rg3 (5 mg/kg dosage, **A--C**), iv administration of 20(R)-Rg3 (5 mg/kg dosage, **D--F**), ig administration of 20(S)-Rg3 (50 mg/kg dosage, **G**) and ig administration of 20(R)-Rg3 (50 mg/kg dosage, **H**) in rats (*n* = 6). Adopted from [@B66].](fphar-09-00188-g005){#F5}

Discussions and Outlook
=======================

*Panax notoginseng* is a traditional Chinese medical drug rich in dammarane-type tetracyclic triterpenoid saponins. Some naturally existed major saponins will be deglycosylated or dehydrated to become secondary saponins during the heating processing of *P. notoginseng*. Researches on the chemical components of raw and processed notoginseng indicate that the transformation of compound basis is the basic reason for the changes in their pharmacological effects. A majority of these secondary saponins are stereoisomeric saponins which have been tentatively assigned to be "biomarkers" in processed notoginseng. Available investigations reveal that a diversity of distinctly different pharmacological activities, pharmacokinetic behaviors exhibits between two saponin stereoisomers.

The phenomenon of stereoisomerism has gained great attention on chemical drugs by many pharmaceutical enterprises. A very famous example is the disaster caused by thalidomide in 1960s in pharmaceutical history. 8000--12000 infants were born to be limb malformed owing to the exposure to this drug during the pregnancy period of their mothers ([@B54]). The reason is that the structure of thalidomide is racemic, with R-(+) conformation exhibiting high anti-epileptic effect, while S-(-) conformation presenting strong teratogenic effect. However, the pharmacological difference in these two epimers has not been recognized at that time. Lessons have been learned from this tragedy that the separation and the study of drug stereoisomers are of great importance. With the development of the research on stereoisomeric drugs in recent years, the best four selling drug on the list of top ten global ranking list in 2006 were chiral drugs which were optically pure. However, stereoisomerism of natural compounds has not been studied extensively. Although stereoisomeric saponins have already attracted the interest of researchers, the investigations on the pharmacological differences have only been focused on ginsenoside Rg~3~ and Rh~2~, which are far below enough. More studies on pharmacological activities of minor saponin isomers produced in processed notoginseng, biological difference and pharmacokinetic behaviors in stereoisomeric saponins and the underlying mechanisms, and the preparation methods of stereoisomeric saponins need to be performed. Moreover, other cost-effective, efficient, and environmentally friendly microorganic and enzymatic hydrolysis methods for the preparation of optically pure saponins are worthy of further development and exploration. We believe that those researches on stereoisomeric saponins will be beneficial to structure-activity relationship, structure modification and new drug development in phytochemicals.

Author Contributions
====================

TZ and YD formulated the study concept and design of the paper. MP prepared the **Tables [2](#T2){ref-type="table"}**--**[6](#T6){ref-type="table"}**. MP and YY acquired the data, draw the **Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1A){ref-type="table"}**, and drafted the manuscript. JL guided the critical revision of the manuscript and provided important intellectual content. All authors reviewed the manuscript, agreed to all the contents, and agreed the submission.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by the Programs of the National Natural Science Foundation of China (Grant Nos. 81403175 and 81274200); Project of the Shanghai Committee of Science and Technology (Grant No. 13401900301); Youth Talent Sail Plan from Shanghai Committee of Science and Technology (Grant No. 14YF1411300); Project of the Shanghai Municipal Health and Family Planning Commission (Grant Nos. 20134Y053, 2017YQ072, and 201740152); Research Fund for the Doctoral Program of Shanghai (Grant No. B201703); and Xinglin Scholar Plan.

[^1]: Edited by: *Matthias F. Melzig, Freie Universität Berlin, Germany*

[^2]: Reviewed by: *Pinarosa Avato, Università degli Studi di Bari Aldo Moro, Italy; Min Ye, Peking University, China*

[^3]: ^†^*These authors have contributed equally to this work.*

[^4]: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
